Company Performance Metrics
Signal12 is an ophthalmic drug company that develops therapies for ocular graft-versus-host disease and related ocular surface disorders. The company focuses on Pro-ocular, a proprietary topical gel formulated for forehead application to stimulate tear and meibomian gland function via neural pathways. Signal12 conducts clinical trials, including
Phase 2 studies in ocular graft-versus-host disease and dry eye disease, to evaluate safety, efficacy, and patient adherence. Its work centers on advancing Pro-ocular into Phase 3 clinical trials and preparing for commercialization. Signal12 also collaborates with academic and clinical partners to generate clinical data and refine therapeutic approaches for patients with chronic ocular complications after stem cell transplantation.
